Table 2.

Risks factors for event-free survival and overall survival

OutcomesEvents/evaluableHR (95% CI)P
Event-free survival
 Age at transplantation, y
  ≤684/6381.00<.001
  7-1587/4391.46 (1.07-2.00).017
  16-2514/333.03 (1.68-5.47)<.001
Donor type
  HLA-matched relative108/6771.00<.001
  HLA-mismatched relative29/782.75 (1.81-4.16)<.001
  HLA-matched unrelated26/2521.25 (0.75-2.07).39
  HLA-mismatched unrelated22/1031.60 (0.95-2.71).08
 Conditioning regimen
  Bu/Cy/TT/FLU28/3761.00<.001
  Bu/Cy/FLU27/2591.32 (0.78-2.25).31
  Bu/Cy71/2493.11 (1.80-5.40)<.001
  Treosulfan/TT/FLU38/1692.79 (1.61-4.83)<.001
  Bu or melphalan ± TT ± FLU21/575.09 (2.81-9.21)<.001
 Transplant period
  2012-201674/6571.00.008
  2006-201173/3391.66 (1.17-2.35).01
  2000-200538/1141.96 (1.16-3.33).01
Overall survival
Age at transplantation, y
  ≤657/6381.00<.001
  7-1573/4391.84 (1.29-2.63)<.001
  16-2512/334.35 (2.28-8.30)<.001
Donor type
  HLA-matched relative83/6771.00<.001
  HLA-mismatched relative25/783.30 (1.93-4.77)<.001
  HLA-matched unrelated19/2521.13 (0.64-2.02).67
  HLA-mismatched unrelated15/1031.56 (0.85-2.88).16
Conditioning regimen
  Bu/Cy/TT/FLU25/3761.00<.001
  Bu/Cy/FLU22/2591.32 (0.74-2.34).34
  Bu/Cy55/2493.61 (2.15-6.07)<.001
  Treosulfan/TT/FLU30/1692.22 (1.23-4.030.008
  Bu or melphalan ± TT ± FLU10/572.55 (1.18-5.50).02